DUBLIN (BUSINESS WIRE) The "Molecular Diagnostics for Cancer: Markets Forecasts by Cancer Type, Product, and Place with Executive & Consultant Guides and Customization" report has been added to ResearchAndMarkets.com's offering.Key Topics Covered:1 Molecular Dx Oncology Market - Strategic Situation Analysis with I.
7 Molecular Diagnostics Recent Developments
7.1 Recent Developments - Importance and How to Use This Section
7.1.1 Importance of These Developments
7.1.2 How to Use This Section
7.2 Nucleix to Invest in Early-Stage Lung Cancer Dx
7.3 Invitae to Acquire Genosity for $200M
7.4 Bio-Techne Obtains CE Mark for Exosomal Liquid Biopsy Prostate Test
7.5 Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience
7.6 Natera Revenues Grow 35 Percent
7.7 AnchorDx Closes $40M Financing Round
7.8 Exact Sciences Strategy for End-to-End Cancer Testing
7.9 Genomics England: Whole Genome Sequencing for Cancer Patients to Launch
7.10 Singlera Genomics Closes $150M Funding for Cancer Screening
7.11 Biocartis GeneproDx, Endpoint Health Collaborate on Tests for Idylla Platform
A market with fundamental growth factors is impacted by the COVID-19 Pandemic.
Molecular Diagnostics for Cancer is positioned to directly benefit from the explosion in genomics knowledge but shifting resources to deal with the COVID emergency may interrupt growth. Learn all about it in this new report. the publisher includes a special segment, Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. And now over 130 companies are profiled. A range of dynamic trends are pushing market growth and company valuations.
Working against this dynamic market are the forces of the COVID Driven Recession. The publisher s latest numbers factor in the different COVID forces, their timing, and their effect on growth.